Metzner H J, Hermentin P, Cuesta-Linker T, Langner S, Müller H G, Friedebold J
Centeon Pharma GmbH, Marburg, Germany.
Haemophilia. 1998;4 Suppl 3:25-32. doi: 10.1046/j.1365-2516.1998.0040s3025.x.
In order to provide patients with von Willebrand disease a factor VIII (FVIII)/von Willebrand factor (vWF) concentrate of reproducible quality, an SDS-agarose gel electrophoresis method has been established to determine the content of the high molecular weight multimers (band 11 and higher) of vWF. This method has been used to characterize the content of high molecular weight vWF multimers in Humate P/Haemate P, a commercial FVIII/vWF concentrate. The average content of high molecular weight vWF multimers of 47 batches of Humate P/Haemate P has been determined to be 84.1% of the corresponding bands in normal human plasma. Use of this multimer analysis method for the characterization of five further commercial products revealed clear differences with respect to the high molecular weight vWF multimer content. Furthermore, there is a linear correlation (r2 = 0.73) between the content of high molecular weight vWF multimers and the specific activity of vWF (determined as vWF:RCoF/vWF:Ag). The method described here for analysis of the content of high molecular weight vWF multimers is a reliable and reproducible method to characterize this class of factor concentrates with respect to vWF multimer composition.
为了给血管性血友病患者提供质量可重现的凝血因子VIII(FVIII)/血管性血友病因子(vWF)浓缩物,已建立一种SDS-琼脂糖凝胶电泳方法来测定vWF高分子量多聚体(条带11及以上)的含量。该方法已用于表征商业FVIII/vWF浓缩物Humate P/Haemate P中高分子量vWF多聚体的含量。已测定47批Humate P/Haemate P中高分子量vWF多聚体的平均含量为正常人血浆中相应条带的84.1%。使用这种多聚体分析方法对另外五种商业产品进行表征,结果显示在高分子量vWF多聚体含量方面存在明显差异。此外,高分子量vWF多聚体的含量与vWF的比活性(测定为vWF:RCoF/vWF:Ag)之间存在线性相关性(r2 = 0.73)。本文所述的用于分析高分子量vWF多聚体含量的方法是一种可靠且可重现的方法,可用于表征这类因子浓缩物的vWF多聚体组成。